

**GOVERNMENT OF INDIA  
MINISTRY OF HEALTH AND FAMILY WELFARE  
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA  
UNSTARRED QUESTION NO. 2998  
TO BE ANSWERED ON 19<sup>TH</sup> AUGUST, 2025**

**PROMOTION OF INDIAN PHARMACOPOEIA**

**2998: SHRI SAKET GOKHALE:**

Will the **Minister of HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) the steps taken by the Ministry to ensure that Indian Pharmacopoeia is recognized as a book of standards by a greater number of foreign countries; and
- (b) the issues, if any, that are hindering the recognition of Indian Pharmacopoeia by other countries and the steps taken to address these issues?

**ANSWER**

**THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY  
WELFARE  
(SMT. ANUPRIYA PATEL)**

(a) & (b): In order to promote recognition of the Indian Pharmacopoeia (IP) in a greater number of countries, the Indian Pharmacopoeia Commission (IPC), under the aegis of the Union Ministry of Health and Family Welfare, continuously engages with foreign nations and their national regulatory authorities.

In this regard, two Policy Makers' Fora have been organized in 2024 and 2025 with participation from 37 countries, primarily from the Global South. The 15th International Meeting of the World Pharmacopoeia (IMWP) was also convened in February 2025 in collaboration with the World Health Organization to enhance cooperation among global pharmacopoeias and regulatory bodies. As a result of these initiatives, the IP is currently recognized in 17 countries, of which 12 have recognized it in the last two years. This international recognition of IP facilitates Indian pharmaceutical exports, enhances global market access and boosts credibility of Indian medicines globally.

Further, sustained efforts are being undertaken to increase global recognition of the IP with the objective of facilitating its acceptance in the drug regulatory frameworks of other countries. These include bilateral technical discussions during Joint Working Group meetings with other countries as well as participation in international conferences and symposia.

\*\*\*\*\*